Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD



(MedPage Today) — NEW ORLEANS — Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments